๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

GS-2872 clinical trials

Source: EU Clinical Trials Information System (CTIS) — the 2 authorised or ongoing trials that list a product named GS-2872. It is not named in any ClinicalTrials.gov record in our registers. Synced 26 Sep 2026
2EU trials (CTIS)
0With a site in Ireland
1Lead sponsor
1Register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from EU CTIS registry records ยท Last verified ยท Editorial standards
At a glance

GS-2872 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 3. The sponsor is Gilead Sciences Inc. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.

01

GS-2872 in the EU trials register (CTIS)

2 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named GS-2872. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
2025-524336-19-00 · Virus Diseases
Phase 3 Ongoing Gilead Sciences Inc Poland, Italy, France + 3 more
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00 · Virus Diseases
Phase 3 Ongoing Gilead Sciences Inc Netherlands, Poland, Germany + 3 more
02

Conditions studied with GS-2872

1 condition
Virus Diseases2
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Gilead Sciences Inc2
04

By country register

RegisterTrialsRecruiting
EU register (CTIS)2—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

05

Questions about GS-2872 trials

How many clinical trials are testing GS-2872?

2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named GS-2872, as of the registry sync on 26 September 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.

Who sponsors GS-2872 clinical trials?

The lead sponsor is Gilead Sciences Inc. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how GS-2872 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how GS-2872 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GS-2872 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.